title: Psoriasis and psoriatic arthritis overview.
abstract: Psoriasis and psoriatic arthritis (PsA) are chronic immune-mediated diseases that primarily affect the skin and joints, respectively; these diseases are also associated with high rates of cardiovascular and other comorbidities. Despite over 40 genes proven to be related to the disease, the exact causes of psoriasis and PsA are still to be determined. Recent insights into the underlying pathophysiology of these diseases have revealed novel therapeutic targets. Effective management requires timely diagnosis and initiation of treatment. Yet, both psoriasis and PsA remain underrecognized and undertreated in current clinical practice. Recognizing the true physical, social, and emotional burden of psoriasis and PsA, as well as their associated comorbidities, is the first step to improving the prognosis for affected patients.
authors.affiliation: amderm@gmail.com.
authors.forename: Alan
authors.initials: A
authors.lastname: Menter
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000453:epidemiology / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D019468:Disease Management; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D011379:Prognosis; D011565:Psoriasis / Q000453:epidemiology / Q000276:immunology / Q000503:physiopathology* / Q000628:therapy*; D011788:Quality of Life; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents